Literature DB >> 32415627

Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: Imaging at 1 vs 3 hours and planar vs SPECT/CT.

Brett W Sperry1,2, Eric Burgett3, Kevin A Bybee3,4, A Iain McGhie3,4, James H O'Keefe3,4, Ibrahim M Saeed3,4, Randall C Thompson3,4, Timothy M Bateman3,4.   

Abstract

BACKGROUND: Multi-societal consensus recommendations endorse both planar and single photon emission tomographic (SPECT) image acquisitions for the evaluation of cardiac amyloidosis. However, the correlation between planar and SPECT findings and the optimal timing of image acquisitions remain uncertain.
METHODS: This is an analysis of 109 consecutive patients who underwent technetium pyrophosphate nuclear scintigraphy for the evaluation of cardiac amyloidosis. Patients were imaged at 1 and 3 hours after radiotracer injection using both planar and SPECT/CT, and the correlations between imaging protocols were compared.
RESULTS: In the overall cohort (median age 77 years, 75% male), 33 patients had radiotracer localized to the myocardium on SPECT/CT images. There was strong correlation between 1- and 3-hour planar heart-to-contralateral lung ratios (mean difference 0.07, r = 0.94). However, there was discordance between planar image interpretation (based upon semiquantitative score and H/CL ratio) and myocardial localization of radiotracer on SPECT/CT in 17 patients (16%). The pattern of SPECT/CT uptake was identical at 1 and 3 hours in all cases (32 diffuse, 1 focal).
CONCLUSION: These data support the recommendation that SPECT/CT should be obtained in addition to planar images when performing nuclear scintigraphy for the detection of cardiac amyloidosis. A 1-hour planar and SPECT/CT protocol appears optimal.

Entities:  

Keywords:  Cardiomyopathy; SPECT; amyloid heart disease; heart failure; image analysis; image interpretation

Year:  2020        PMID: 32415627     DOI: 10.1007/s12350-020-02139-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  6 in total

1.  Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis.

Authors:  Golnaz Roshankar; Geneva C White; Sebastien Cadet; Nowell M Fine; Denise Chan; James A White; Victor Jimenez-Zepeda; Piotr J Slomka; Robert J H Miller
Journal:  J Nucl Cardiol       Date:  2021-10-03       Impact factor: 3.872

Review 2.  99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.

Authors:  Nobuhiro Tahara; Olivier Lairez; Jin Endo; Atsushi Okada; Mitsuharu Ueda; Tomonori Ishii; Yoshinobu Kitano; Hahn-Ey Lee; Eleonora Russo; Toru Kubo
Journal:  ESC Heart Fail       Date:  2021-11-29

3.  Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.

Authors:  Zhaoye Wu; Chunjing Yu
Journal:  BMC Cardiovasc Disord       Date:  2021-10-07       Impact factor: 2.298

4.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Authors:  Timothy J Poterucha; Pierre Elias; Sabahat Bokhari; Andrew J Einstein; Albert DeLuca; Mona Kinkhabwala; Lynne L Johnson; Kathleen R Flaherty; Sunil E Saith; Jan M Griffin; Adler Perotte; Mathew S Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2020-11-18

5.  Pitfalls of the Semi-Quantitative Analyzing 99mTc-Pyrophosphate Planar Images for Diagnosing Transthyretin Cardiac Amyloidosis: A Possible Solution.

Authors:  Yuankai Zhu; Ruping Pan; Dan Peng; Qingjian Dong; Xiaohua Zhu
Journal:  Diagnostics (Basel)       Date:  2022-01-01

Review 6.  Transthyretin cardiac amyloidosis: a review of the nuclear imaging findings with emphasis on the radiotracers mechanisms.

Authors:  Teodor M Ionescu; Wael Jalloul; Cati R Stolniceanu; Roxana Iacob; Laura P Grecu; Ana-Maria Stătescu; Irena Grierosu; Mihai Guțu; Adrian Gavrilescu; Crișu Daniela; Antoniu Petriș; Manuela Ciocoiu; Cristina Ungureanu; Cipriana Ștefănescu
Journal:  Ann Nucl Med       Date:  2021-07-17       Impact factor: 2.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.